PepGen (PepGen) Interest Coverage : N/A (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is PepGen Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. PepGen's Operating Income for the three months ended in Mar. 2024 was $-19.80 Mil. PepGen's Interest Expense for the three months ended in Mar. 2024 was $0.00 Mil. GuruFocus does not calculate 's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. PepGen Inc has enough cash to cover all of its debt. Its financial situation is stable.

The historical rank and industry rank for PepGen's Interest Coverage or its related term are showing as below:

PEPG's Interest Coverage is not ranked ^*
in the Biotechnology industry.
Industry Median: 144.99
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

PepGen Interest Coverage Historical Data

The historical data trend for PepGen's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

PepGen Interest Coverage Chart

PepGen Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Interest Coverage

No Debt

N/A

PepGen Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Coverage	Get a 7-Day Free Trial									N/A	N/A	N/A	N/A	N/A

Competitive Comparison of PepGen's Interest Coverage

For the Biotechnology subindustry, PepGen's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PepGen's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PepGen's Interest Coverage distribution charts can be found below:

* The bar in red indicates where PepGen's Interest Coverage falls into.

PepGen Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage

-1

Operating Income

Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt ⁽¹⁾.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

PepGen's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, PepGen's Interest Expense was $0.00 Mil. Its Operating Income was $-84.77 Mil. And its Long-Term Debt & Capital Lease Obligation was $17.10 Mil.

GuruFocus does not calculate PepGen's interest coverage with the available data.

PepGen's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Here, for the three months ended in Mar. 2024, PepGen's Interest Expense was $0.00 Mil. Its Operating Income was $-19.80 Mil. And its Long-Term Debt & Capital Lease Obligation was $16.74 Mil.

GuruFocus does not calculate PepGen's interest coverage with the available data.

The higher the ratio, the stronger the company's Financial Strength is.

PepGen (NAS:PEPG) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

PepGen Interest Coverage Related Terms

Thank you for viewing the detailed overview of PepGen's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.

PepGen (PepGen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PepGen Inc (NAS:PEPG) » Definitions » Interest Coverage

Comparable Companies

Traded in Other Exchanges

N/A

Address

321 Harrison Avenue, 8th Floor, Boston, MA, USA, 02118

Website

https://www.pepgen.com

PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.

Executives

James G Mcarthur	director, officer: President and CEO	NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453
Jaya Goyal	officer: See Remarks	PEPGEN INC., 245 MAIN ST., CAMBRIDGE MA 02142
Habib J Dable	director	C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
James E Flynn	10 percent owner, other: *Possible Member of 10% Group	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Laurie Keating	director	300 THIRD STREET, CAMBRIDGE MA 02142
Christopher Ashton	director	PEPGEN INC., 245 MAIN ST., CAMBRIDGE MA 02142
Deerfield Management Company, L.p. (series C)	10 percent owner, other: *Possible Member of 10% Group	345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Michelle L Mellion	officer: See Remarks	PEPGEN INC., 245 MAIN ST., CAMBRIDGE MA 02142
Noel Donnelly	officer: Chief Financial Officer	PEPGEN INC., 245 MAIN ST., CAMBRIDGE MA 02142
Niels Svenstrup	officer: See Remarks	PEPGEN INC., 245 MAIN ST., CAMBRIDGE MA 02142
Sonia Bracegirdle	officer: See Remarks	PEPGEN INC., 245 MAIN ST., CAMBRIDGE MA 02142
Deerfield Mgmt V, L.p.	10 percent owner, other: *Possible Member of 10% Group	345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Deerfield Private Design Fund V, L.p.	10 percent owner, other: *Possible Member of 10% Group	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Oxford Science Enterprises Plc	10 percent owner	46 WOODSTOCK ROAD, OXFORD X0 OX2 6HT